KalVista Pharmaceuticals, Inc. Common Stock
KALVKalVista Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of novel, oral protease inhibitors for the treatment of hereditary angioedema (HAE) and other medical conditions. Founded in 2009 and based in the United States, the company aims to advance targeted therapies to improve patient outcomes through innovative drug development and clinical programs.
Company News
U.S. stock futures advanced on Friday as investors awaited the December jobs report and the Supreme Court's ruling on Trump's tariffs. Major indices showed modest gains with SPY and QQQ trading higher in premarket. Key movers included General Motors facing EV investment losses, Tilray surging on earnings beats, Offerpad jumping on Trump's housing...
KalVista Pharmaceuticals launched EKTERLY, its first oral treatment for hereditary angioedema, generating $1.4 million in Q1 FY2026 revenue. The launch was accompanied by increased commercialization expenses and a widened net loss, reflecting the company's transition to commercial operations.
The FDA approved Ionis Pharmaceuticals' Dawnzera, the first RNA-targeted medicine for preventing hereditary angioedema (HAE) attacks in patients 12 and older, demonstrating significant attack rate reduction in clinical trials.
The angioedema treatment market is expected to grow due to the rising prevalence of allergic conditions and increasing awareness of hereditary angioedema (HAE). The pipeline analysis shows over 15 companies are developing 20+ angioedema drugs, with promising therapies in different clinical trial phases.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Keybanc raised the price target for CrowdStrike Holdings, Inc. (NASDAQ: CRWD) from $318 to $375. Keybanc analyst Eric Heath maintained an Overweight rating...
